Choudhary Research Overview

Choudhary lab 2022Choudhary lab 2022

Research Statement:

The focus of the research in my lab is to evaluate the mechanisms underlying vascular dysfunction and cardiac dysfunction seen in pulmonary vascular diseases.  The laboratory uses a variety of in vitro, ex vivo, and in vivo approaches utilizing the preclinical models of pulmonary hypertension and emphysema.  In clinical and epidemiological research, we are attempting to characterize the role and impact of cardiac dysfunction in settings of lung diseases, and study the epidemiology of pulmonary hypertension.

Research Focus Areas:

For a complete list of published work, click here.

Current Funding:

Funding Agency: National Institutes of Health, NHLBI R01 HL148727
Role:  Principal Investigator
Title:  Role of Endothelial Anoactamin-1 In Pulmonary Arterial Hypertension 
Funding Period: 07/01/2019 - 06/30/2023
Funding Agency: Department of Veterans Affairs, PULM-004-18S
Role: Principal Investigator
Title: Role of Skeletal Muscle Mitochondrial Supercomplexes in Exercise Intolerance
Funding Period: 07/01/2019 - 06/30/2023
Funding Agency: National Institutes of Health, NIGMS, P20GM103652  
Role:  Co-Principal Investigator
Title:   Endothelial Injury and Repair: CardioPulmonary Vascular Biology COBRE 
Funding period:  09/20/2013 - 05/31/2023

Direct Costs:  $2,064,137 

Funding Agency: Department of Defense, W81XWH-19-1-0763 (Savitz)
Role: Co-Investigator
Title: Impact of Open Burn Pit Exposure on Respiratory and Cardiovascular Health Among Military Veterans   
Funding Period: 09/15/2019 – 09/14/2022
Funding Agency: National Institutes of Health, NIGMS, U54 GM115677 (Rounds) 
Role: Director, Pilot Projects Core, Co- Investigator 
Title: Advance Clinical and Translational Research (Advance-CTR)   
Funding Period: 08/10/2021-07/09/2026 
Funding Agency: Industry Sponsored Clinical Trial (AstraZeneca AB)
Role: Site Principal Investigator
Title: DELIVER - Dapagliflozin Evaluation to Improve the LIVEs of Patients with PReserved Ejection Fraction Heart Failure
Funding Period: 2019 - 2024 
PREVENTABLE- Pragmatic Evaluation of Events and Benefits of Lipid-lowering in Older Adults
Sponsor: National Institute of Ageing
Trial Period: 2021-
Role: Site Principal Investigator